Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
-
Experimental CAR-T therapy targets rare muscle disease
Disease control Recruiting nowThis early-phase study tests an experimental cell therapy called GC012F in 12 people with refractory idiopathic inflammatory myopathy, a rare autoimmune disease causing muscle weakness and inflammation. Participants receive a single infusion of their own modified immune cells aft…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
Could CAR t cells tame multiple sclerosis? early trial launches
Disease control Recruiting nowThis early study tests whether a new treatment called GC012F (a CAR T cell injection) is safe and tolerable for people with multiple sclerosis. About 15 participants will receive the therapy and be monitored for side effects over 15 years. The goal is to see if this immune-cell a…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New cell therapy trial hopes to tame Hard-to-Treat muscle weakness
Disease control Recruiting nowThis early study tests an experimental treatment called GC012F for people with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. Six participants will receive the injection to see if it is safe and shows signs of helping control the disease. Th…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Engineered immune cells take on multiple sclerosis and other autoimmune disorders
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 05, 2026 11:57 UTC